Influence of pentoxifylline on natural cytotoxicity and expression of granzymes and PI-9, a specific granzyme B inhibitor

International Journal of Molecular Medicine

Volumn 17, Issue 1, 2006, Pages 135-139

  Lazarczyk, Maciej ^a,b   Dziunycz, Piotr ^a   Niderla, Justyna ^a   Milewski, Lukasz ^a   Lazarczyk, Marta Alicja ^a   Boszczyk, Anna ^a   Samaha, Robert ^a   Grzela, Tomasz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Granzyme; Methylxanthine; Natural cytotoxicity; Pentoxifylline; PI 9

Indexed keywords

BUCLADESINE; GRANZYME; GZMA PROTEIN, HUMAN; GZMB PROTEIN, HUMAN; GZMH PROTEIN, HUMAN; PENTOXIFYLLINE; PERTUSSIS TOXIN; PHOSPHODIESTERASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SERPINB9 PROTEIN, HUMAN;

ARTICLE; CELL STRAIN K 562; CYTOLOGY; GENETICS; HUMAN; METABOLISM; MONONUCLEAR CELL;

BUCLADESINE; GRANZYMES; HUMANS; K562 CELLS; LEUKOCYTES, MONONUCLEAR; PENTOXIFYLLINE; PERTUSSIS TOXIN; PHOSPHODIESTERASE INHIBITORS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SERPINS;

EID: 33644875217     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.1.135     Document Type: Article

References (30)

1. Semmler J, Gebert U, Eisenhut T, Moeller J, Schonharting MM, Allera A and Endres S: Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78: 520-525, 1993.
2. Bessler H, Gilgal R, Djaldetti M and Zahavi I: Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 40: 747-754, 1986.
3. Ohshima N and Sato M: Effect of pentoxifylline on microvascular blood flow velocity. Angiology 32: 752-763, 1981.
4. Mueller R: On the therapy of disturbances of blood fluidity. Angiology 1: 226-234, 1985.
5. Aviado DM and Porter JM: Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 4: 297-307, 1984.
6. Yamac K, Kaptan KM, Beyan C, Teksin ZS, Agabeyoglu IT and Gokgoz L: Comparison of the hematological effects of a sustained release chitosan formulation of pentoxifylline with a commercial formulation. Arzneimittelforschung 50: 827-831, 2000.
7. Lindgarde F, Jelnes R, Bjorkman H, Adielsson G, Kjellstrom T, Palmquist I and Stavenow L: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 80: 1549-1556, 1989.
8. Johnsson R: Effect of pentoxifylline on red cell flexibility and cation transport in healthy subjects and patients with hereditary spherocytosis. Scand J Haematol 23: 81-87, 1979.
9. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT and Strandness DE: Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104: 66-72, 1982.
10. Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Incandela L, Geroulakos G, Ramaswami G, Cazaubon M, Barsotti A, Vasdekis S, Bavera P and Ippolito E: Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial. Angiology 53 (Suppl 1): 1-5, 2002.
11. Vernimmen F, Verheye-Dua F, Du Toit H and Böhm L: Effect of pentoxifylline on radiation damage and tumor growth. Strahlenther Onkol 10: 595-601, 1994.
12. Grzela T, Lazarczyk M, Niderla J, Golab J, Lazarczyk MA and Skopinski P: Pentoxifylline promotes development of murine colon adenocarcinoma-derived metastatic tumors in liver. Oncol Rep 10: 1805-1809, 2003.
13. Lazarczyk M, Grzela T, Niderla J, Lazarczyk MA, Milewski L, Dziunycz P, Skopinski P and Golab J: Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanomaderived metastatic tumor development in lungs. Oncol Rep 11: 1121-1125, 2004.
14. Dominguez-Jimenez C, Sancho D, Nieto M, Montoya MC, Barreiro O, Sanchez-Madrid F and Gonzalez-Amaro R: Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol 71: 588-596, 2002.
15. Lazarczyk M, Grzela T, Niderla J, Golab J, Korczak-Kowalska G, Oldak M and Skopinski P: Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. Oncol Rep 10: 839-843, 2003.
16. Van Furth AM, Verhard-Seijmonsbergen EM, van Furth R and Langermans JA: Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta, IL-10 by human leucocytes. Immunology 91: 193-196, 1997.
17. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Trinchieri G and Karp CL: Inhibition of human interleukin-12 production by pentoxifylline. Immunology 91: 197-203, 1997.
18. Thanhauser A, Reiling N, Bohle A, Toellner KM, Duchrow M, Sheel D, Schluter C, Ernst M, Flad HD and Ulmer AJ: Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology 80: 151-156, 1993.
19. Lazarczyk M, Grzela T, Korczak-Kowalska G, Niderla J, Oldak M, Jozwiak J and Skopinski P: Pentoxifylline inhibits perforin-dependent natural cytotoxicity in vitro. Oncol Rep 9: 423-426, 2002.
20. Nagy Z, Sipka R, Ocsovszki I, Balogh A and Mandi Y: Suppressive effect of pentoxifylline on natural killer cell activity; experimental and clinical studies. Naunyn Schmiedebergs Arch Pharmacol 359: 228-234, 1999. (Pubitemid 29142874)
21. Hoskin DW, Phu T and Makrigiannis AP: Pentoxifylline inhibits granzyme B and perforin expression following T-lymphocyte activation by anti-CD3 antibody. Int J Immunopharmacol 18: 623-631, 1996. (Pubitemid 27117934)
22. Lazarczyk M, Grzela T, Niderla J, Lazarczyk MA, Dziunycz P, Milewski L and Samaha R: Influence of pentoxifylline on perforin expression in human PBMC. Int J Mol Med 14: 725-728, 2004.
23. Sun J, Bird CH, Sutton V, et al: A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 271: 27802-27809, 1996. (Pubitemid 26367355)
24. Medema JP, De Jong J, Peltenburg LTC, et al: Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 98: 11515-11520, 2001. (Pubitemid 32928760)
25. Grzela T, Krauze A, Grzela K, et al: Impaired apoptosis of lymphocytes derived from patient with decreased expression of caspase-8 results in ALPS-like phenotype. Int J Mol Med 14: 937-942, 2004.
26. Grzela T, Chudzinski W, Lazarczyk M, et al: Persisted/recurrent hyperparathyroidism associated with development of multi-drug resistance phenotype and proliferation of parathyroid transplants. Int J Mol Med 14: 595-599, 2004.
27. Grzela T, Lazarczyk M, Oldak M and Korczak-Kowalska G: Influence of culture medium pH on cytotoxicity of CD95L in vitro. Folia Histochem Cytobiol 39: 29-33, 2001. (Pubitemid 32117848)
28. Trapani JA: Granzymes: a family of lymphocyte granule serine proteases. Genome Biol 12: 3014.1-3014.7, 2001.
29. Baker E, Sayers TJ, Sutherland GR and Smyth MJ: The genes encoding NLK cell granule serine proteases, human tryptase-2 (TRYP2) and human granzyme A (HFSP), both map to chromosome 5q11-q12 and define a new locus for cytotoxic lymphocyte granule tryptases. Immunogenetics 40: 235-237, 1994. (Pubitemid 24217867)
30. Salvesen G, Farley D, Shuman J, Przybyla A, Reilly C and Travis J: Molecular cloning of human cathepsin G: structural similarity to mast cell and cytotoxic lymphocyte proteinases. Biochemistry 26: 2289-2293, 1987. (Pubitemid 17080972)